Active Filter(s):
Details:
With this acquisition Pocono plans to consolidate capabilities at both facilities to expand on enhancing revenue stream opportunities and in-house product development, specifically our abuse deterrent technology for opioid based transdermal medications.
Lead Product(s): Opioid based transdermal medications
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Nutriband
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 16, 2020